Nanoscope's MCO-010 Gene Therapy Progresses with FDA Support for Retinitis Pigmentosa Treatment

Nanoscope Therapeutics Inc. has provided an update on its MCO-010 optogenetic gene therapy for Retinitis Pigmentosa (RP). Following discussions with the FDA and the Icelandic Medicines Agency, the FDA suggested that a change in visual acuity in low vision RP patients could be a suitable primary efficacy measure in a study. MCO-010, designed for severe vision loss in advanced RP, holds orphan drug and fast track designations from the FDA.